146 related articles for article (PubMed ID: 35125713)
1. Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome.
Singh C; Jain A; Takkar A; Agarwal A; Rohilla M; Lad D; Khadwal A; Basher R; Radotra BD; Bal A; Das A; Gupta V; Lal V; Varma S; Malhotra P; Prakash G
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):68-77. PubMed ID: 35125713
[TBL] [Abstract][Full Text] [Related]
2. Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.
Yerram P; Reiss SN; Modelevsky L; Schaff L; Reiner AS; Panageas KS; Grommes C
Ann Lymphoma; 2023 Feb; 7():. PubMed ID: 37067886
[TBL] [Abstract][Full Text] [Related]
3. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
4. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.
Villanueva G; Guscott M; Schaiquevich P; Sampor C; Combs R; Tentoni N; Hwang M; Lowe J; Howard S
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900250
[TBL] [Abstract][Full Text] [Related]
7. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.
Seidel S; Kowalski T; Margold M; Baraniskin A; Schroers R; Martus P; Schlegel U
Ther Adv Neurol Disord; 2020; 13():1756286420951087. PubMed ID: 33101460
[TBL] [Abstract][Full Text] [Related]
8. Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences.
Patekar M; Adhikari N; Biswas A; Raina V; Kumar L; Mohanti BK; Gogia A; Sharma A; Batra A; Bakhshi S; Garg A; Thulkar S; Sharma MC; Vishnubhatla S; Baghmar S; Sahoo RK
J Glob Oncol; 2019 Feb; 5():1-9. PubMed ID: 30811305
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
10. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
[TBL] [Abstract][Full Text] [Related]
11. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.
Garwood MJ; Hawkes EA; Churilov L; Chong G
Cancer Chemother Pharmacol; 2020 Jan; 85(1):133-140. PubMed ID: 31848681
[TBL] [Abstract][Full Text] [Related]
12. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis.
Seidel S; Korfel A; Kowalski T; Margold M; Ismail F; Schroers R; Baraniskin A; Pels H; Martus P; Schlegel U
Neurol Res Pract; 2019; 1():17. PubMed ID: 33324883
[TBL] [Abstract][Full Text] [Related]
13. Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome.
Seidel S; Margold M; Kowalski T; Baraniskin A; Schroers R; Korfel A; Thiel E; Weller M; Martus P; Schlegel U
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208229
[TBL] [Abstract][Full Text] [Related]
14. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].
Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S
Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.
Kim J; Kim TG; Lee HW; Kim SH; Park JE; Lee M; Kim YZ
Curr Oncol; 2021 Nov; 28(6):4655-4672. PubMed ID: 34898570
[TBL] [Abstract][Full Text] [Related]
17. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
[TBL] [Abstract][Full Text] [Related]
19. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
